Compare GLBS & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | MDAI |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | Greece | United States |
| Employees | N/A | 78 |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7M | 39.6M |
| IPO Year | 2010 | N/A |
| Metric | GLBS | MDAI |
|---|---|---|
| Price | $2.17 | $2.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | $3.00 |
| AVG Volume (30 Days) | 55.9K | ★ 395.3K |
| Earning Date | 06-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $20.20 | $23.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.18 |
| 52 Week High | $2.44 | $3.21 |
| Indicator | GLBS | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 75.76 |
| Support Level | $1.51 | $2.30 |
| Resistance Level | $2.23 | $2.80 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 41.46 | 98.35 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.